Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the
“Company”), a biotechnology company focused on discovering and
developing novel antibody immunotherapies that help the immune system
fight cancer and other diseases, today announced that Arthur H.
Tinkelenberg, Ph.D., Enumeral’s President and Chief Executive Officer,
will participate in the 2016 East/West CEO Conference on the panel
entitled “Academia and Industry: Challenges and Synergies,” on Sunday,
January 10, 2016 at 1:30 p.m. Pacific Time. The conference will be held
at the Four Seasons Hotel in San Francisco, CA.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel
antibody immunotherapies that help the immune system fight cancer and
other diseases. The Company is building a pipeline focused on
next-generation checkpoint modulators, with initial targets including
PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these
agents, Enumeral’s researchers apply a proprietary immune profiling
technology platform that measures functioning of the human immune system
at the level of individual cells, providing key insights for candidate
selection and validation. For more information on Enumeral, please visit www.enumeral.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160106005413/en/
Copyright Business Wire 2016